Scynexis Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • SCYX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.59
  • (As of Thursday Closing)

Scynexis General Information

Description

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1 Evertrust Plaza
  • 13th Floor
  • Jersey City, NJ 07302
  • United States
+1 (201)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 1 Evertrust Plaza
  • 13th Floor
  • Jersey City, NJ 07302
  • United States
+1 (201)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Scynexis Stock Performance

As of 19-Nov-2026, Scynexis’s stock price is $2.59. Its current market cap is $25.9M with 10M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.59 $2.82 $2.51 - $9.12 $25.9M 10M 224K -$0.23

Scynexis Financials Summary

As of 30-Sep-2026, Scynexis has a trailing 12-month revenue of $18.9M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (2,987) (9,105) (7,019) 9,707
Revenue 18,881 20,601 3,746 140,141
EBITDA (12,306) (10,613) (24,600) 66,935
Net Income (10,102) (8,609) (21,288) 67,041
Total Assets 67,951 59,027 90,643 128,412
Total Debt 1,821 2,175 16,270 15,080
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Scynexis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Scynexis‘s full profile, request access.

Request a free trial

Scynexis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Scynexis‘s full profile, request access.

Request a free trial

Scynexis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infective
Drug Discovery
Jersey City, NJ
29 As of 2023

Cambridge, MA
 

Dallas, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Scynexis Competitors (35)

One of Scynexis’s 35 competitors is Spero Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spero Therapeutics Formerly VC-backed Cambridge, MA
Peloton Therapeutics Formerly VC-backed Dallas, TX
F2G Venture Capital-Backed Macclesfield, United Kingdom
Paratek Pharmaceuticals Private Equity-Backed King of Prussia, PA
Melinta Therapeutics Private Equity-Backed Parsippany, NJ
You’re viewing 5 of 35 competitors. Get the full list »

Scynexis Patents

Scynexis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4836771-A1 Triterpenoid antifungals for use in the treatment of mucormycosis Pending 05-Jan-2024
WO-2025147685-A1 Triterpenoid antifungals for use in the treatment of mucormycosis Inactive 05-Jan-2024
AU-2021250655-A1 Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd) Active 02-Apr-2020
AU-2021250655-B2 Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd) Active 02-Apr-2020
US-12310949-B2 Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd) Active 02-Apr-2020 A61K31/4365
To view Scynexis’s complete patent history, request access »

Scynexis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Scynexis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Scynexis‘s full profile, request access.

Request a free trial

Scynexis Investments (1)

Scynexis’s most recent deal was a Corporate Asset Purchase with Poxel (SCY-770) for . The deal was made on 31-Mar-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Poxel (SCY-770) 31-Mar-2026 Corporate Asset Purchase Buildings and Property
To view Scynexis’s complete investments history, request access »

Scynexis ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Scynexis’s complete esg history, request access »

Scynexis FAQs

  • When was Scynexis founded?

    Scynexis was founded in 1999.

  • Where is Scynexis headquartered?

    Scynexis is headquartered in Jersey City, NJ.

  • What is the size of Scynexis?

    Scynexis has 29 total employees.

  • What industry is Scynexis in?

    Scynexis’s primary industry is Drug Discovery.

  • Is Scynexis a private or public company?

    Scynexis is a Public company.

  • What is Scynexis’s stock symbol?

    The ticker symbol for Scynexis is SCYX.

  • What is the current stock price of Scynexis?

    As of 19-Nov-2026 the stock price of Scynexis is $2.59.

  • What is the current market cap of Scynexis?

    The current market capitalization of Scynexis is $25.9M.

  • What is Scynexis’s current revenue?

    The trailing twelve month revenue for Scynexis is $18.9M.

  • Who are Scynexis’s competitors?

    Spero Therapeutics, Peloton Therapeutics, F2G, Paratek Pharmaceuticals, and Melinta Therapeutics are some of the 35 competitors of Scynexis.

  • What is Scynexis’s annual earnings per share (EPS)?

    Scynexis’s EPS for 12 months was -$0.23.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process